

Astiva Health earned a **4-Star Rating**
from CMS for **2026 Overall Quality**



The Centers for Medicare & Medicaid Services (CMS) evaluates Medicare Advantage and Part D prescription drug plans on a 1 to 5-star scale each year.



astiva^h HEALTH

PROVIDER NEWSLETTER

Summer 2026

A Message from the CEO

This summer, I am proud to share a milestone that reflects the trust our community has placed in Astiva Health, and more importantly, the providers who make that trust possible every single day. We have grown to serve more than 50,000 members across our network. This growth is not simply just a number, but a reflection of the relationships that our participating providers have built and the quality of care they provide for each of the members.

I'm proud to inform you that, for the second straight year, Astiva Health has earned the distinction of being a 4-star health plan from CMS. On behalf of Astiva Health, thank you for your dedication to our members, your commitment to quality, and your continued partnership with us. As we look forward to the remainder of this plan year and beyond, I am excited about what we, together, will accomplish for our members.

Tri T. Nguyen, M.D.
CEO, Astiva Health

COMPLIANCE: Annual Model of Care Training

The **Model of Care** is a foundational CMS requirement under the Special Needs Plan (SNP) framework. Annual provider training ensures our network delivers coordinated, person-centered care to our members – particularly those with chronic conditions, complex clinical needs, or dual eligibility status. Consistent Completion of MOC Training demonstrates our collective commitment to high-quality care.

This training is to be completed within 60 days of contracting or employment and annually thereafter.

How to Complete Your Training

Training is completed online through our Website. Follow the steps below to ensure timely completion and proper documentation of your attestation.

- STEP 1** Go to www.AstivaHealth.com and select **MOC Training** under Provider tab.
- STEP 2** Complete the **MOC Training Model** by viewing our training materials.
- STEP 3** Submit Your Attestation by completing the **Training Attestation Form**.



PHARMACY UPDATES:

Traditionally, Medicare has covered GLP-1 drugs for conditions such as **type 2 diabetes** or certain cardiovascular conditions, but not for obesity alone. The **Medicare GLP-1 Bridge Program** is a new temporary Medicare pilot program that begins July 1, 2026 and runs through December 31, 2027.

It is designed to help eligible Medicare beneficiaries access certain GLP-1 weight-loss medications at a much lower cost—typically a \$50 monthly copay.

IMPORTANT DETAILS

- The program operates **outside the normal Medicare Part D benefit structure**. CMS uses a central processor for approvals and pharmacy payments.
- The \$50 copays generally **do not count toward the member's Part D out-of-pocket spending cap**.
- Coverage is currently scheduled to end after December 2027 unless extended or replaced.

For more information from CMS about GLP-1 Bridge, please scan the QR Code:



SCAN ME

PHARMACY

A Formulary Update for Prescribers

As Medicare formularies continue to evolve, understanding our 2026 preferred options within the same therapeutic class can help support both high-quality patient care and medication affordability. This update outlines our preferred **denosumab** option and its implications for your patients.

DENOSUMAB PRODUCTS: Stoboclo Therapeutic Equivalence

- ☒ **Stoboclo** is a biosimilar to Prolia, with both products containing **denosumab** as the active ingredient. They share the same mechanism of action, FDA-approved indications, dosing schedule, and expected clinical outcomes. Patients can anticipate comparable efficacy and safety with either therapy.
- ☒ **Stoboclo vs Prolia Formulary Status**
Under the 2026 Astiva Health formulary, Stoboclo is designated as a preferred brand medication (Tier 3), offering lower out-of-pocket costs for members. Prolia is non-covered and requires prior authorization; when approved, it is subject to a Tier 4 non-preferred brand copay.
- ☒ **Supporting Adherence Through Cost-Effective Prescribing**
Prescribing formulary-preferred therapies when clinically appropriate helps reduce financial burden, promote adherence, and support optimal patient outcomes in the Medicare population.
- ☒ **Key Takeaway for Prescribers**
For Astiva Health members requiring Denosumab, Stoboclo provides therapeutic equivalence to Prolia but with meaningful formulary and cost advantages.



astiva^h HEALTH
Provider Relations:

Phone: (833) 300-0910
Fax: (714) 908-8246

Email: ProviderSupport@astivahealth.com
Website: astivahealth.com

QUALITY IMPROVEMENT

Annual Wellness Review Program

The **Annual Wellness Review Program** serves as a foundation for preventive care planning, early identification of health risks, and closing critical care gaps. Astiva Health is pleased to continue offering this incentive program to eligible participating physicians who complete the program requirements. Providers interested in participating, may contact the Provider Relations Department at ProviderSupport@astivahealth.com or **(888) 333-0910** for additional information and enrollment assistance.

To view your current AWW completion rate and incentive payment status, please log-in to the Provider Portal and navigate to the AWW section. If you need portal access, please contact Provider Relations Department.

PROVIDER NETWORK

Demographic Update

**NEW
UPDATE**

Important Reminder:

Timely updates ensure members can locate and access your services without interruption. If any of the demographic information has changed, please notify Astiva Health immediately by email at:

ProviderSupport@astivahealth.com

PROVIDER RELATIONS CONTACT INFORMATION:

Phone: (833) 300-0910

Fax: (714) 908-8246

Email: ProviderSupport@astivahealth.com

Website: astivahealth.com